Related Experiment Videos
Radiolabeled octreotide. What lessons for antibody-mediated targeting?
1Department of Nuclear Medicine, St. Bartholomews Hospital, London.
Cell Biophysics
|August 1, 1992
Summary
Radiolabeled octreotide analogs target somatostatin receptors on tumors for diagnostics. Differences in excretion pathways (kidney vs. liver) inform the design of future antibody-like imaging agents.
Area of Science:
- Radiopharmaceutical chemistry
- Molecular imaging
- Oncology
Background:
- Octreotide, a somatostatin analog, targets somatostatin receptors overexpressed in various tumors.
- Neuroendocrine tumors, lymphomas, and some adenocarcinomas exhibit high somatostatin receptor density.
Purpose of the Study:
- To synthesize and evaluate radiolabeled octreotide analogs for diagnostic imaging of somatostatin receptor-positive tumors.
- To compare the pharmacokinetic profiles of different radiolabeled octreotide derivatives.
Main Methods:
- Synthesis of tyrosine- and DTPA-containing octreotide analogs.
- Radiolabeling with iodine-123 (123I) and indium-111 (111In).
- In vivo evaluation of tumor targeting, sensitivity, specificity, and pharmacokinetic properties.
Main Results:
- Radiolabeled octreotide analogs showed high sensitivity and specificity for targeting SMS receptor-positive tumors.
- Rapid tumor uptake and blood clearance were observed for both radiopharmaceuticals.
- 123I-Tyr3-octreotide was primarily excreted via the hepatobiliary system, while 111In-DTPAPhe1-octreotide was mainly eliminated renally.
Conclusions:
- Radiolabeled octreotide analogs are effective diagnostic agents for tumors expressing somatostatin receptors.
- Pharmacokinetic differences between radiolabeled analogs highlight the importance of tracer design.
- Small antibody-like tracers may offer advantages over larger antibody formats for tumor imaging.